Advanced search
Publication Cover
Leukemia & Lymphoma Volume 55, 2014 - Issue 4
Submit an article Journal homepage
529
Views
34
CrossRef citations to date
0
Altmetric
Letters to the Editor

Simplification of risk stratification for splenic marginal zone lymphoma: a point-based score for practical use

Carlos MontalbanDepartment of Pathology and Translational Research, M. D. Anderson Cancer Center, Madrid, SpainCorrespondence[email protected]
,
Victor AbrairaClinical Biostatistics Unit, Hospital Ramon y Cajal, IRYCIS, Madrid, Spain and CIBERESP, Spain
,
Luca ArcainiDepartment of Molecular Medicine, University of Pavia and Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
,
Eva Domingo-DomenechDepartment of Hematology, Hospital Duran i Reynals, ICO, Barcelona, Spain
,
Pablo Guisado-VascoDepartment of Internal Medicine, Hospital Quirón San Camilo, Madrid, Spain
,
Emilio IannittoDepartment of Oncology-Hematology, Ospedale S.G. Moscati, ASL, Taranto, Italy
,
Manuela MollejoDepartment of Pathology, Hospital Virgen de la Salud, Toledo, Spain
,
Estella MatutesDepartment of Haemato-Oncology, Royal Marsden Hospital/Institute of Cancer, London, UK
,
Andres J. M. FerreriUnit of Lymphoid Malignancies, San Raffaele Scientific Institute, Milan, Italy
,
Antonio SalarDepartment of Hematology, Hospital del Mar, Barcelona, Spain
,
Sara RattottiDepartment of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
,
Andrea CarpanetoUOC Ematologia Ospedale Sant’Anna, Ronciglione, Viterbo, Italy
,
Ricardo PerezDepartment of Oncology, Hospital Gregorio Marañon, Madrid, Spain
,
Jose-Luis BelloDepartment of Hematology, Hospital Universitario, Santiago de Compostela, Spain
,
Miguel HernandezDepartment of Hematology, Hospital Universitario de Canarias, Tenerife, Spain
,
Dolores CaballeroDepartment of Hematology, Hospital Clínico, Salamanca, Spain
,
Felix CarbonellDepartment of Hematology, Hospital General Universitari, Valencia, Spain
,
Miguel A. PirisDepartment of Pathology, Hospital Marques de Valdecilla, Santander, Spain
& for the Splenic Marginal Zone Lymphoma Study Group (SMZLSG) show all
Pages 929-931 | Received 29 Apr 2013, Accepted 16 Jun 2013, Published online: 29 Jul 2013

References

  • Swerdlow SH, Campos E, Harris NL, et al. Pathology and genetics of tumors of hematopoietic and lymphoid tissues. World Health Organization classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC Press; 2008.
  • Matutes E, Oscier D, Montalban C, et al. Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria. Leukemia 2008;22:487–495.
  • Montalbán C, Abraira V, Arcaini L, et al. Risk stratification for splenic marginal zone lymphoma based on haemoglobin concentration, platelet count, high lactate dehydrogenase level and extrahilar lymphadenopathy: development and validation on 593 cases. Br J Haematol 2012;159:164–171.
  • Pencina MJ, D’Agostino RB Sr, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011;30:11–21.
  • Tsimberidou AM, Catovsky D, Schlette E, et al. Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone. Cancer 2006;107:125–135.
  • Bennet M, Yegena S, Dave HP, et al. Rituximab monotherapy is highly effective in splenic marginal zone lymphoma. Hematol Oncol 2008;26:114.
  • Kalpadakis C, Pangalis GA, Dimopoulous MN, et al. Rituximab monotherapy is highly effective in splenic marginal zone lymphoma. Hematol Oncol 2007;25:127–131.
  • Kalpadakis C, Pangalis GT, Angelopoulou MK, et al. Treatment of splenic marginal zone lymphoma with rituximab monotherapy: progress report and comparison with splenectomy. Oncologist 2013; 18:190–197.
  • Else M, Marin-Niebla A, de la Cruz F, et al. Rituximab, used alone or in combination, is superior to other treatment modalities in splenic marginal zone lymphoma. Br J Haematol 2012;159:322–328.
  • Cervetti G, Galimberti S, Sordi E, et al. Significant efficacy of 2-CdA with or without rituximab in the treatment of splenic marginal zone lymphoma (SMZL). Ann Oncol 2010;21:851–854.
  • Iannitto E, Luminari S, Mammi C, et al. Non-pegylated lyposomal doxorubicin, cyclophosphamide, vincristine, prednisone and rituximab (R-COMP) as initial treatment for patients with splenic marginal zone lymphoma (SMZL): GISL study. Blood 2007; 110(Suppl. 1) : Abstract 1292.
  • Iannitto E, Tripodo C. How I diagnose and treat splenic lymphomas. Blood 2011;117:2585–2595.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.